Change of Nrf2 expression in rat hippocampus in a model of chronic cerebral hypoperfusion

International Journal of Neuroscience

Volumn 124, Issue 8, 2014, Pages 577-584

  Yang, Ying ^a   Zhang, Junjian ^a   Liu, Hui ^a   Zhang, Lei ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Chronic cerebral hypoperfusion; Hippocampus; Nuclear factor erythroid 2 related factor 2; Oxidative stress

Indexed keywords

TRANSCRIPTION FACTOR NRF2; NFE2L2 PROTEIN, RAT;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; BINDING AFFINITY; BRAIN PERFUSION; CAROTID ARTERY OBSTRUCTION; CHRONIC CEREBRAL HYPOPERFUSION; COGNITIVE DEFECT; COMMON CAROTID ARTERY; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; GEL MOBILITY SHIFT ASSAY; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA2 REGION; HIPPOCAMPAL CA3 REGION; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; LEARNING DISORDER; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; SPATIAL LEARNING; ANIMAL; BIOSYNTHESIS; CEREBROVASCULAR DISEASE; CHRONIC DISEASE; DISEASE MODEL; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; VASCULARIZATION; WISTAR RAT;

ANIMALS; CEREBROVASCULAR DISORDERS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HIPPOCAMPUS; MALE; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; RATS; RATS, WISTAR;

EID: 84903846097     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2013.863196     Document Type: Article

References (36)

1. de la Torre JC. Alzheimer's disease is a vasocognopathy: A new term to describe its nature. Neurol Res 2004; 26: 517-24
2. De Jong GI, De Vos RA, Steur EN, Luiten PG. Cerebrovascular hypoperfusion: A risk factor for Alzheimer's diseasë Animal model and postmortem human studies. Ann N Y Acad Sci 1997; 826: 56-74
3. Ruitenberg A, den Heijer T, Bakker SL, et al. Cerebral hypoperfusion and clinical onset of dementia: The Rotterdam Study. Ann Neurol 2005; 57: 789-94
4. Sarti C, Pantoni L, Bartolini L, Inzitari D. Cognitive impairment and chronic cerebral hypoperfusion: What can be learned from experimental models. J Neurol Sci 2002; 203-4: 263-6
5. Scheel P, Puls I, Becker G, Schoning M. Volume reduction in cerebral blood flow in patients with vascular dementia. Lancet 1999; 354: 2137
6. de la Torre JC. Critically attained threshold of cerebral hypoperfusion: The CATCH hypothesis of Alzheimer's pathogenesis. Neurobiol Aging 2000; 21: 331-42
7. Liu H, Zhang J. Cerebral hypoperfusion and cognitive impairment: The pathogenic role of vascular oxidative stress. Int J Neurosci 2012; 122: 494-9
8. Huang L, He Z, Guo L, Wang H. Improvement of cognitive deficit and neuronal damage in rats with chronic cerebral ischemia via relative long-Term inhibition of rho-kinase. Cell Mol Neurobiol 2008; 28: 757-68
9. Yan X, Zhang JJ, Li X, et al. Green tea polyphenols inhibit cognitive impairment induced by chronic cerebral hypoperfusion viamodulating oxidative stress. JNutr Biochem 2009; 21: 741-8
10. He XL, Wang YH, Gao M, et al. Baicalein protects rat brain mitochondria against chronic cerebral hypoperfusion-induced oxidative damage. Brain Res 2009; 1249: 212-21
11. KobayashiM, Yamamoto M. Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Adv Enzyme Regul 2006; 46: 113-40
12. Johnson JA, Johnson DA, Kraft AD, et al. The Nrf2-ARE pathway: An indicator and modulator of oxidative stress in neurodegeneration. Ann N Y Acad Sci 2008; 1147: 61-9
13. de Vries HE, Witte M, Hondius D, et al. Nrf2-induced antioxidant protection: A promising target to counteract ROS-mediated damage in neurodegenerative diseasë Free Radic Biol Med 2008; 45: 1375-83
14. Itoh K, Wakabayashi N, Katoh Y, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-Terminal Neh2 domain. Genes Dev 1999; 13: 76-86
15. Calkins MJ, Jakel RJ, Johnson DA, et al. Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription. Proc Natl Acad Sci USA 2005; 102: 244-9
16. Shih AY, Imbeault S, Barakauskas V, et al. Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo. J Biol Chem 2005; 280: 22925-36
17. Satoh T, Okamoto SI, Cui J, et al. Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic [correction of electrophillic] phase II inducers. Proc Natl Acad Sci USA 2006; 103: 768-73
18. Satoh T, Kosaka K, Itoh K, et al. Carnosic acid, a catecholtype electrophilic compound, protects neurons both in vitro and in vivo through activation of the Keap1/Nrf2 pathway via S-Alkylation of targeted cysteines on Keap1. J Neurochem 2008; 104: 1116-31
19. Hickenbottom SL, Grotta JC, Strong R, et al. Nuclear factorkappaB and cell death after experimental intracerebral hemorrhage in rats. Stroke. 1999; 30: 2472-7, 2477-8
20. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke 2011; 42: 2672-713
21. Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol 2001; 64: 575-611
22. Farkas E, Luiten PG, Bari F. Permanent, bilateral common carotid artery occlusion in the rat: A model for chronic cerebral hypoperfusion-related neurodegenerative diseases. Brain Res Rev 2007; 54: 162-80
23. Jiwa NS, Garrard P, Hainsworth AH. Experimental models of vascular dementia and vascular cognitive impairment: A systematic review. J Neurochem 2010; 115: 814-28
24. Ohta H, NishikawaH, Kimura H, et al.Chronic cerebral hypoperfusion by permanent internal carotid ligation produces learning impairment without brain damage in rats. Neuroscience 1997; 79: 1039-50
25. Otori T, Katsumata T, Muramatsu H, et al. Long-Term measurement of cerebral blood flow and metabolism in a rat chronic hypoperfusion model. Clin Exp Pharmacol Physiol 2003; 30: 266-72
26. Tsuchiya M, Sako K, Yura S, Yonemasu Y. Cerebral blood flow and histopathological changes following permanent bilateral carotid artery ligation in Wistar rats. Exp Brain Res 1992; 89: 87-92
27. Butterfield DA, Sultana R. Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: Insights into the progression of this dementing disorder. J Alzheimers Dis 2007; 12: 61-72
28. Hensley K, Maidt ML, Yu Z, et al. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci 1998; 18: 8126-32
29. Calkins MJ, Johnson DA, Townsend JA, et al. The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxid Redox Signal 2009; 11: 497-508
30. Scapagnini G, Vasto S, Abraham NG, et al. Modulation of Nrf2/ARE pathway by food polyphenols: A nutritional neuroprotective strategy for cognitive and neurodegenerative disorders. Mol Neurobiol 2011; 44: 192-201
31. Andersen JK. Oxidative stress in neurodegeneration: Cause or consequenceñat Med 2004; Suppl(S18-25
32. Barhwal K, Hota SK, Jain V, et al. Acetyl-l-carnitine (ALCAR) prevents hypobaric hypoxia-induced spatial memory impairment through extracellular related kinase-mediated nuclear factor erythroid 2-related factor 2 phosphorylation. Neuroscience. 2009; 161: 501-14
33. Liao Y, Wang R, Tang XC. Centrophenoxine improves chronic cerebral ischemia induced cognitive deficit and neuronal degeneration in rats. Acta Pharmacol Sin 2004; 25: 1590-1596
34. Shih AY, Johnson DA, Wong G, et al. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci 2003; 23: 3394-406
35. Fahey JW, Talalay P. Antioxidant functions of sulforaphane: A potent inducer of Phase II detoxication enzymes. Food Chem Toxicol 1999; 37: 973-9
36. Zhao J, Kobori N, Aronowski J, Dash PK. Sulforaphane reduces infarct volume following focal cerebral ischemia in rodents. Neurosci Lett 2006; 393: 108-12